



Public Health
England

National Cancer Intelligence Network

Service Profiles HPB and OG

Julie Konfortion, Victoria Coupland and Sue Knights

Profiles - Rationale

Benchmark and assess

NHS Trust / multi-disciplinary team (MDT) based

Assist clinical teams to reflect on outcomes

Assist the commissioners of cancer services to

- *understand the variation across the MDT's (local service) for both patient experience and patient care.*

Indicators included have been

- *discussed with commissioners and clinicians as being important and form the basis for objective dialogue about clinical practice and service delivery.*

What do profiles show?

- Size (Generic)
- Demographics (Generic)
- Specialist Team (Generic)
- Throughput (Generic)
- Waiting Times (Generic)
- Practice (Site Specific)
- Outcomes and Recovery (Site Specific)
- Patient Experience (Generic)

Service profiles

Section	#	Indicator	No. of patients/cases or value	Percentage or rate			Trust rate or percentage compared to England				Source	Period
				Trust	Lower 95% Confidence Limit	Upper 95% Confidence Limit	England	Lowest	Range	Highest		
				England Median								
Size	OG1	Number of NOGCA patients	31	n/a	n/a	n/a	10,614	0		301	NOGCA	2011-2012
	G2	Number of newly diagnosed patients per year	93	n/a	n/a	n/a	11,877	13		199	NCDR	2010
Demographics	G3	Patients (from #G2) aged 70+	48	52 %	42 %	62 %	62 %	39 %		90 %	NCDR	2010
	G4	Patients (from #G2) with recorded ethnicity	93	100 %	96 %	100 %	96 %	82 %		100 %	NCDR	2010
	G5	Patients (from #G2) with recorded ethnicity which is not White-British	27	29 %	21 %	39 %	7 %	0 %		64 %	NCDR	2010
	G6	Patients (from #G2) who are Income Deprived (1)	n/a	13 %	n/a	n/a	15 %	7 %		33 %	NCDR	2010
	G7	Male patients (from #G2)	52	56 %	46 %	66 %	66 %	51 %		81 %	NCDR	2010
Specialist Team	G8	Peer review: Does the specialist team have full membership? (2)	IV	Yes	n/a	n/a	n/a	n/a	n/a	n/a	NCPDR	2011/2012
	G9	Peer review: Proportion of peer review indicators met	IV	88 %	n/a	n/a	85 %	9 %		97 %	NCPDR	2011/2012
	G10	Peer review: are there immediate risks? (3)	IV	No	n/a	n/a	n/a	n/a	n/a	n/a	NCPDR	2011/2012
	G11	Peer review: are there serious concerns? (3)	IV	No	n/a	n/a	n/a	n/a	n/a	n/a	NCPDR	2011/2012
	G12	CPES: Patients surveyed and % reporting being given name of a CNS (4)	132	68 %	n/a	n/a	74 %	48 %		92 %	CPES	2011/2012
Throughput	G13	Number of urgent GP referrals for suspected cancer	1	n/a	n/a	n/a	109,367	0		2030	CWT	2011/2012
	G14	Estimated proportion of tumours with emergency presentations [experimental]	n/a	2 %	0 %	8 %	23 %	2 %		86 %	HES	2011/2012
Waiting time	G15	Urgent GP referrals for suspected cancer seen within 2 weeks	0	100 %	0 %	100 %	94 %	82 %		100 %	CWT	2013/14 Q3
	G16	Treatment within 62 days of urgent GP referral for suspected cancer	4	50 %	24 %	86 %	78 %	25 %		100 %	CWT	2013/14 Q3
	G17	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental]	1	100 %	21 %	100 %	5 %	0 %		100 %	CWT	2013
	G18	Cases treated that are urgent GP referrals for suspected cancer [experimental]	80	31 %	25 %	37 %	36 %	8 %		82 %	CWT	2011/2012
	G19	First treatment began within 31 days of decision to treat	48	98 %	89 %	100 %	99 %	90 %		100 %	CWT	2013/14 Q3
Practice	OG2	Number of new oesophageal cases managed per year	40	43 %	33 %	63 %	55 %	33 %		76 %	NCDR	2010
	OG3	Number of new stomach cases managed per year	53	57 %	47 %	67 %	45 %	24 %		87 %	NCDR	2010
	OG4	Oesophageal cancer confirmed histology	39	98 %	87 %	100 %	93 %	48 %		100 %	NCDR	2010
	OG5	Stomach cancer confirmed histology	50	94 %	85 %	99 %	91 %	68 %		100 %	NCDR	2010
	OG6	Number of O-G resections	11	14 %	8 %	24 %	18 %	0 %		69 %	NCDR	Jan-Sept 2010
	OG7	Patients who had a CT scan	200	99 %	97 %	100 %	91 %	71 %		99 %	NOGCA	2011-2012
	OG8	Patients with EUS investigation	34	64 %	51 %	77 %	62 %	30 %		100 %	NOGCA	2011-2012
	OG9	Patients with palliative treatment intent	80	74 %	66 %	82 %	47 %	32 %		74 %	NOGCA	2011-2012
	OG10	NCPDR Network Board compliance	SA	100.0 %	n/a	n/a	n/a	0.0 %	n/a	100.0 %	NCPDR	2010-2011
	OG11	NCPDR NSSG compliance	IV	73.0 %	n/a	n/a	n/a	0.0 %	n/a	100.0 %	NCPDR	2010-2011
	Outcomes and Recovery	OG12	30 day mortality (adjusted)	43	0.0 %	n/a	n/a	n/a	n/a	n/a	n/a	NOGCA
OG13		90 day mortality (adjusted)	43	2.3 %	n/a	n/a	n/a	n/a	n/a	n/a	NOGCA	2011-2012
OG14		Oesophageal cancer relative survival one year	n/a	42.5	38.4	46.6	n/a	36.8	n/a	46.9	UKCIS	2005-2009
OG15		Stomach cancer relative survival one year	n/a	45.4	41.2	49.6	42.2	37.1		51.6	UKCIS	2005-2009
OG16		Reoperation (adjusted)	43	13.2 %	n/a	n/a	n/a	n/a	n/a	n/a	NOGCA	2011-2012
OG17		Anastomotic leak (adjusted)	43	4.4 %	n/a	n/a	n/a	n/a	n/a	n/a	NOGCA	2011-2012
Patient Experience	G20	Patients surveyed & % reporting always being treated with respect & dignity (5)	132	78 %	n/a	n/a	79 %	61 %		95 %	CPES	2011/2012
	G21	Number of viable survey questions and % of those questions scoring red (6)	70	9 %	n/a	n/a	n/a	0 %	n/a	54 %	CPES	2011/2012
	G22	Number of viable survey questions and % of those questions scoring green (6)	70	19 %	n/a	n/a	n/a	4 %	n/a	100 %	CPES	2011/2012

OG Profile: Practice

Practice	OG2	Number of new oesophageal cases managed per year	?
	OG3	Number of new stomach cases managed per year	?
	OG4	Oesophageal cancer confirmed histology	?
	OG5	Stomach cancer confirmed histology	?
	OG6	Number of O-G resections	?
	OG7	Patients who had a CT scan	?
	OG8	Patients with EUS investigation	?
	OG9	Patients with palliative treatment intent	?
	OG10	NCPR Network Board compliance	?
	OG11	NCPR NSSG compliance	?

OG Profile: Outcomes & Recovery

Outcomes and Recovery	OG12	30 day mortality (adjusted)	?
	OG13	90 day mortality (adjusted)	?
	OG14	Oesophageal cancer relative survival one year	?
	OG15	Stomach cancer relative survival one year	?
	OG16	Reoperation (adjusted)	?
	OG17	Anastomotic leak (adjusted)	?

What do profiles show for HPB?

- Size
 - Number of newly diagnosed patients
 - By Primary Liver, Pancreatic, Ampulla of Vater, Gall Bladder & Biliary Tract

Cancer type	ICD-10	Number of diagnoses
Primary liver cancer	C22.0, C22.2 - C22.9	2,200
Biliary tract cancer	C22.1, C24.0, C24.8 - C24.9	1,852
Gallbladder cancer	C23	621
Ampulla of Vater cancer	C24.1	356
Pancreatic cancer	C25 (C25.0 - C25.9)	7,058

What do profiles show for HPB?

- Demographics
 - Patients over 70+ and Income Deprived (split as above)
- Specialist Team (Generic)
- Throughput
 - Emergency Presentations only (split as above)

What do profiles show for HPB?

- Waiting Times NOT INCLUDED IN THIS PROFILE
- Practice NOT INCLUDED IN THIS PROFILE
- Outcomes and Recovery (Site Specific)
 - One Year and Five Year Survival (split as above)
 - 30 and 90 day mortality (Pancreatic and Ampulla of Vater)(Resected colorectal patients undergoing surgery for liver metastases – future version)
- Patient Experience NOT INCLUDED IN THIS PROFILE

Service Profile

Select Trust/MDT:


County Durham and Darlington NHS Foundation Trust MDT - UHND

HPB 2013/14 - County Durham and Darlington NHS Foundation Trust MDT - UHND

Export to PDF

Group by None
 Cancer Sub Type **Liver**
 Section

- Trust/MDT is significantly different from England mean
- Trust/MDT is not significantly different from England mean
- Statistical significance cannot be assessed
- ◆ England mean



Size	G1	Number of new cases (invasive and non-invasive) managed per year, 2012 NOT INCLUDED IN THIS PROFILE
	L1	Primary liver cancer number of newly diagnosed patients per year
	G4	Patients (from #G2) with recorded ethnicity NOT INCLUDED IN THIS PROFILE
	G5	Patients (from #G4) with recorded ethnicity which is not White-British NOT INCLUDED IN THIS PROFILE
	L2	Primary liver cancer: Patients (from #L1) aged 70+
	L3	Primary liver cancer: Patients (from #L1) who are Income Deprived ¹
	L4	Primary liver cancer: Male patients (from #L1)
	L5	Primary liver cancer: Confirmed histology (from #L1)
	L7	Primary liver cancer: Age-standardised incidence rate - males
Demographics (based on newly diagnosed patients, 2010 ⁷)	L8	Primary liver cancer: Age-standardised incidence rate - females
	G8	Peer review: does the specialist team have full membership? (2)
	G9	Peer review: proportion of peer review indicators met
	HPB1	Peer review: proportion of peer review indicators met (Specialist Pancreatic put forward as liver resection)
	G10	Peer review: are there immediate risks? (3)
	G11	Peer review: are there serious concerns? (3)
Specialist Team	G12	CPES (4): Patients surveyed and % reporting being given name of a CNS (5,6) NOT INCLUDED IN THIS PROFILE
	G13	Number of urgent GP referrals for suspected cancer NOT INCLUDED IN THIS PROFILE
	L6	Primary liver cancer: Estimated proportion of tumours with emergency presentations (from #L1) [experimental] ²
	L9	Primary liver cancer: One-year relative survival
Throughput	G15	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks NOT INCLUDED IN THIS PROFILE
	G16	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer NOT INCLUDED IN THIS PROFILE
	G17	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] NOT INCLUDED IN THIS PROFILE
	G18	Cases treated that are urgent GP referrals with suspected cancer [experimental] NOT INCLUDED IN THIS PROFILE
	G19	Q2 2012/13: First treatment began within 31 days of decision to treat NOT INCLUDED IN THIS PROFILE
Waiting times	L10	Primary liver cancer: Five-year relative survival
	G50	Patients surveyed & % reporting always being treated with respect & dignity (6) NOT INCLUDED IN THIS PROFILE
Outcomes and Recovery	G51	Number of survey questions and % of those questions scoring red(8) NOT INCLUDED IN THIS PROFILE
	G52	Number of survey questions and % of those questions scoring green(8) NOT INCLUDED IN THIS PROFILE
	G52	Number of survey questions and % of those questions scoring green(8) NOT INCLUDED IN THIS PROFILE
Patient Experience - CPES (4)	G51	Number of survey questions and % of those questions scoring red(8) NOT INCLUDED IN THIS PROFILE
	G52	Number of survey questions and % of those questions scoring green(8) NOT INCLUDED IN THIS PROFILE

Service Profile

Select Trust/MDT:

County Durham and Darlington NHS Foundation Trust MDT - UHND


HPB 2013/14 - County Durham and Darlington NHS Foundation Trust MDT - UHND

Export to PDF

Group by

- None
- Cancer Sub Type
- Section
 - Size
 - Demographics
 - Throughput

- Trust/MDT is significantly different from England mean
- Trust/MDT is not significantly different from England mean
- Statistical significance cannot be assessed
- ◆ England mean



Size	G1	Number of new cases (invasive and non-invasive) managed per year, 2012 NOT INCLUDED IN THIS PROFILE	
	L1	Primary liver cancer number of newly diagnosed patients per year	NCDR
	P1	Pancreatic cancer number of newly diagnosed patients per year	NCDR
	AV1	Ampulla of Vater cancer number of newly diagnosed patients per year	NCDR
	GB1	Gallbladder cancer number of newly diagnosed patients per year	NCDR
Throughput	BT1	Biliary tract cancer number of newly diagnosed patients per year	NCDR
	G13	Number of urgent GP referrals for suspected cancer NOT INCLUDED IN THIS PROFILE	
	L6	Primary liver cancer: Estimated proportion of tumours with emergency presentations (from #L1) [experimental] ²	NCDR
	P6	Pancreatic cancer: Estimated proportion of tumours with emergency presentations (from #P1) [experimental] ²	NCDR
	AV6	Ampulla of Vater cancer: Estimated proportion of tumours with emergency presentations (from #AV1) [experimental] ²	NCDR
	GB6	Gallbladder cancer: Estimated proportion of tumours with emergency presentations (from #GB1) [experimental] ²	NCDR
	BT6	Biliary tract cancer: Estimated proportion of tumours with emergency presentations (from #BT1) [experimental] ²	NCDR

Site-specific indicators


Size	G1	Number of new cases (invasive and non-invasive) managed per year, 2012 NOT INCLUDED IN THIS PROFILE	
	L1	Primary liver cancer number of newly diagnosed patients per year	NCDR
	P1	Pancreatic cancer number of newly diagnosed patients per year	NCDR
	AV1	Ampulla of Vater cancer number of newly diagnosed patients per year	NCDR
	GB1	Gallbladder cancer number of newly diagnosed patients per year	NCDR
	BT1	Biliary tract cancer number of newly diagnosed patients per year	NCDR
Demographics (for newly diagnosed patients, 2010?)	G4	Patients (from #G2) with recorded ethnicity NOT INCLUDED IN THIS PROFILE	
	G5	Patients (from #G4) with recorded ethnicity which is not White-British NOT INCLUDED IN THIS PROFILE	
	L2	Primary liver cancer: Patients (from #L1) aged 70+	NCDR
	L3	Primary liver cancer: Patients (from #L1) who are Income Deprived ¹	NCDR
	L4	Primary liver cancer: Male patients (from #L1)	NCDR
	L5	Primary liver cancer: Confirmed histology (from #L1)	NCDR
	L7	Primary liver cancer: Age-standardised incidence rate - males	NCDR
	L8	Primary liver cancer: Age-standardised incidence rate - females	NCDR
	P2	Pancreatic cancer: Patients (from #P1) aged 70+	NCDR
	P3	Pancreatic cancer: Patients (from #P1) who are Income Deprived ¹	NCDR
	P4	Pancreatic cancer: Male patients (from #P1)	NCDR
	P5	Pancreatic cancer: Confirmed histology (from #P1)	NCDR
	P7	Pancreatic cancer: Age-standardised incidence rate - males	NCDR
	P8	Pancreatic cancer: Age-standardised incidence rate - females	NCDR
	AV2	Ampulla of Vater cancer: Patients (from #AV1) aged 70+	NCDR
	AV3	Ampulla of Vater cancer: Patients (from #AV1) who are Income Deprived ¹	NCDR
	AV4	Ampulla of Vater cancer: Male patients (from #AV1)	NCDR
	AV5	Ampulla of Vater cancer: Confirmed histology (from #AV1)	NCDR
	AV7	Ampulla of Vater cancer: Age-standardised incidence rate - males	NCDR
	AV8	Ampulla of Vater cancer: Age-standardised incidence rate - females	NCDR
	GB2	Gallbladder cancer: Patients (from #GB1) aged 70+	NCDR
	GB3	Gallbladder cancer: Patients (from #GB1) who are Income Deprived ¹	NCDR
	GB4	Gallbladder cancer: Male patients (from #GB1)	NCDR
GB5	Gallbladder cancer: Confirmed histology (from #GB1)	NCDR	
GB7	Gallbladder cancer: Age-standardised incidence rate - males	NCDR	
GB8	Gallbladder cancer: Age-standardised incidence rate - females	NCDR	
BT2	Biliary tract cancer: Patients (from #BT1) aged 70+	NCDR	
BT3	Biliary tract cancer: Patients (from #BT1) who are Income Deprived ¹	NCDR	
Specialist Team	BT4	Biliary tract cancer: Male patients (from #BT1)	NCDR
	BT5	Biliary tract cancer: Confirmed histology (from #BT1)	NCDR
	BT7	Biliary tract cancer: Age-standardised incidence rate - males	NCDR
	BT8	Biliary tract cancer: Age-standardised incidence rate - females	NCDR
	G8	Peer review: does the specialist team have full membership? (2)	NPRP
	G9	Peer review: proportion of peer review indicators met	NPRP
	HPB1	Peer review: proportion of peer review indicators met (Specialist Pancreatic put forward as liver resection)	NPRP
	G10	Peer review: are there immediate risks? (3)	NPRP
Throughput	G11	Peer review: are there serious concerns? (3)	NPRP
	G12	CPES (4): Patients surveyed and % reporting being given name of a CNS (5,6) NOT INCLUDED IN THIS PROFILE	
	G13	Number of urgent GP referrals for suspected cancer NOT INCLUDED IN THIS PROFILE	
	L6	Primary liver cancer: Estimated proportion of tumours with emergency presentations (from #L1) [experimental] ²	NCDR
	P6	Pancreatic cancer: Estimated proportion of tumours with emergency presentations (from #P1) [experimental] ²	NCDR
	AV6	Ampulla of Vater cancer: Estimated proportion of tumours with emergency presentations (from #AV1) [experimental] ²	NCDR
Waiting times	GB6	Gallbladder cancer: Estimated proportion of tumours with emergency presentations (from #GB1) [experimental] ²	NCDR
	BT6	Biliary tract cancer: Estimated proportion of tumours with emergency presentations (from #BT1) [experimental] ²	NCDR
	G15	Q2 2012/13: Urgent GP referral for suspected cancer seen within 2 weeks NOT INCLUDED IN THIS PROFILE	
	G16	Q2 2012/13: Treatment within 62 days of urgent GP referral for suspected cancer NOT INCLUDED IN THIS PROFILE	
	G17	Urgent GP referrals for suspected cancer diagnosed with cancer [experimental] NOT INCLUDED IN THIS PROFILE	
Outcomes and Recovery	G18	Cases treated that are urgent GP referrals with suspected cancer [experimental] NOT INCLUDED IN THIS PROFILE	
	G19	Q2 2012/13: First treatment begun within 21 days of decision to treat NOT INCLUDED IN THIS PROFILE	
	L9	Primary liver cancer: One-year relative survival	NCDR
	L10	Primary liver cancer: Five-year relative survival	NCDR
	P9	Pancreatic cancer: One-year relative survival	NCDR
	P10	Pancreatic cancer: Five-year relative survival	NCDR
	P11	Pancreatic cancer: 30 day mortality for head of pancreas surgery	NCDR
	P12	Pancreatic cancer: 90 day mortality for head of pancreas surgery	NCDR
	AV9	Ampulla of Vater cancer: One-year relative survival	NCDR
	AV10	Ampulla of Vater cancer: Five-year relative survival	NCDR
Patient Experience - CPES (4)	AV11	Ampulla of Vater cancer: 30 day mortality for head of pancreas surgery	NCDR
	AV12	Ampulla of Vater cancer: 90 day mortality for head of pancreas surgery	NCDR
	GB9	Gallbladder cancer: One-year relative survival	NCDR
	GB10	Gallbladder cancer: Five-year relative survival	NCDR
	BT9	Biliary tract cancer: One-year relative survival	NCDR
	BT10	Biliary tract cancer: Five-year relative survival	NCDR
	G50	Patients surveyed & % reporting always being treated with respect & dignity (6) NOT INCLUDED IN THIS PROFILE	
	G51	Number of survey questions and % of those questions scoring red(8) NOT INCLUDED IN THIS PROFILE	
	G52	Number of survey questions and % of those questions scoring green(8) NOT INCLUDED IN THIS PROFILE	

Confirmed histology


Emergency presentation

One-year and five-year relative survival


Confirmed histology




Emergency presentations



One-year survival



Five-year survival



Surgery indicators

- 30- and 90- day mortality for England
- Pancreatic cancer - head of pancreas surgery
486 procedures in 2010
30- day mortality 3.7%
90- day mortality 7.2%
- Ampulla of Vater – head of pancreas surgery
165 procedures in 2010
30- day mortality 1.2%
90- day mortality 2.4%

THANK YOU!